Webinar | Drug Product Impurities: Analytical and Toxicological Considerations

Drug product impurities include organic impurities (process- and drug-related), inorganic impurities (elements), residual solvents, and DNA reactive/mutagenic impurities.  Patient safety can only be ensured with adequate identification and toxicological qualification of drug product impurities and degradants.  This two-part webinar will provide an overview of analytical aspects related to impurity identification and will outline requirements for toxicological evaluation and control strategies, including considerations of relevant guidelines and case study examples.

November 5, 2020 | 10 AM EST, 3pm GMT, 4pm CET

By completing this form, you submit your information to the webinar organizer, who will use it to communicate with you regarding this event and their other services.